Global Irritable Bowel Disease (IBD) Market Analysis Report 2024: Increasing Prevalence of Crohn's Disease, and Ulcerative Colitis Driving the $21 Billion Market - Forecasts to 2029 - ResearchAndMarkets.com

The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
星期二, 三月 12, 2024
Information
Tags: 
General Health, Pharmaceutical, Health, Corticosteroid, TNF, Injection (medicine), Growth, Prevalence, Porter's five forces analysis, Incidence, SWOT, Disease, Research, IBD, Market, Medicine, Crohn's disease, Route of administration, Ulcerative colitis, USD, Administration, JAK, Irritable bowel syndrome, Pharmaceutical industry
Geotags: 
ITALY, CANADA, FRANCE, JAPAN, INDIA, AMERICAS, CHINA, EUROPE, UNITED KINGDOM, SPAIN, GERMANY, UNITED STATES
⚠ generated by AI ↴
Organisation: 
RESEARCH AND MARKETS, RESEARCHANDMARKETS.COM
摘要
Key Points: 
  • The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.
  • The increasing incidence and prevalence of Crohn's Disease, and Ulcerative Colitis are major drivers for the growth of the Market.
  • The report analyses the Irritable Bowel Disease Market by Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes)
    The report analyses the Irritable Bowel Disease Market By Route of Administration (Injectable, Oral).
  • The report analyses the Irritable Bowel Disease Market by Indication (Crohn's Disease, Ulcerative Colitis).


The "Global Irritable Bowel Disease Market (2024 Edition): Analysis By Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes), By Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.

The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022. The market was valued at USD 21.45 Billion in 2022 which is expected to reach USD 27.16 Billion in 2029. The increasing incidence and prevalence of Crohn's Disease, and Ulcerative Colitis are major drivers for the growth of the Market.

The report analyses the Irritable Bowel Disease Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).

The global IBD market has been steadily growing, driven by factors such as increasing incidence and prevalence of IBD worldwide. According to recent studies, the prevalence of IBD is rising globally, affecting millions of individuals across all age groups. This increasing prevalence has led to a surge in demand for effective treatments and diagnostics, thereby fueling market growth.

The landscape of IBD treatment has undergone a paradigm shift with continuous therapeutic innovations. Biologic agents targeting specific inflammatory pathways have emerged as effective treatments for moderate to severe IBD, offering improved disease management and symptom control.

Moreover, personalized medicine approaches, driven by advancements in pharmacogenomics and precision medicine, are increasingly being explored to tailor treatments according to individual patient profiles. Furthermore, research into microbiome modulation and gut-targeted therapies holds promise for novel treatment modalities in the future.

The global market for Irritable Bowel Disease is highly competitive, with numerous pharmaceutical companies and biotechnology firms competing for market share.

Scope of the Report

  • The report analyses the Irritable Bowel Disease Market by Value (USD Billion).
  • The report analyses the Irritable Bowel Disease Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
  • The report presents the analysis of Irritable Bowel Disease Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
  • The report analyses the Irritable Bowel Disease Market by Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes)
  • The report analyses the Irritable Bowel Disease Market By Route of Administration (Injectable, Oral).
  • The report analyses the Irritable Bowel Disease Market by Indication (Crohn's Disease, Ulcerative Colitis).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Classes, by Route of Administration & by Indication.
  • Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

Strategic Recommendations

  • Shift towards Small Molecule Therapies
  • Diversification of Therapeutic Targets

Competitive Positioning

  • Companies' Product Positioning
  • Market Position Matrix
  • Market Share Analysis of Irritable bowel disease Market

Company Profiles

  • Johnson & Johnson
  • Pfizer
  • Novartis AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • GSK Plc.
  • UCB S.A
  • Takeda Pharmaceuticals
  • Bristol-Myers Squibb Co.
  • Celltrion

For more information about this report visit https://www.researchandmarkets.com/r/hradkj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Copyright: 
Copyright Business Wire 2024